Does the Lung Cancer Field Need Another Third-Generation EGFR Tyrosine Kinase Inhibitor?
Authors:
- 1 June 2020
- journal article
- editorial
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 15 (6) , 881-883
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M MutationJournal of Thoracic Oncology, 2020
- Simultaneous determination of alflutinib and its active metabolite in human plasma using liquid chromatography–tandem mass spectrometryJournal of Pharmaceutical and Biomedical Analysis, 2019
- Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief ReportJournal of Thoracic Oncology, 2019
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Response to osimertinib following treatment with EGF816 in patients with T790M EGFR mutant NSLCLC.Journal of Clinical Oncology, 2017
- 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trialJournal of Thoracic Oncology, 2016
- Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving RociletinibJAMA Oncology, 2016
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPProceedings of the National Academy of Sciences, 2008